Protein UtilizationNCT07900204
Digestion and Absorption of Postbiotic Regulatory Proteins
A study testing Inactivated Probiotics in people with Protein Utilization, run by Wecare Probiotics Co., Ltd. at 1 site in China.
Trial summary
The goal of this clinical trial is to find out whether a daily postbiotic supplement can help healthy, physically active adults digest and absorb dietary protein better. The main question we aim to answer is: does taking a postbiotic for 12 weeks increase the levels of essential amino acids in the blood after eating a… Read more about this study
- Who is it for?
- Ages 18 to 45 yearsHealthy volunteers can take part
- Conditions the study is for
- Protein Utilization
- What is being tested?
- Inactivated Probiotics
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 100 participants
- Where
- 1 siteChina
- Study dates
- 14 Oct 2026to 6 Mar 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 45 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Age: 18-45 years; open to all genders;
- Body weight has remained stable over the preceding 3 months (change < 5%);
- Willing to maintain their previous dietary and exercise habits with minimal change during the study period;
- Have maintained regular training over the past 3 months, with an average of ≥ 3 sessions/week and each session lasting ≥ 30 minutes;
- Voluntarily participate and sign a written informed consent form, and be able to complete follow-up visits, blood sampling, stool sampling, and questionnaire completion as required.
Who cannot join
- History of or current presence of severe gastrointestinal disorders (e.g., inflammatory bowel disease, significant malabsorption following gastrointestinal surgery), or other conditions that the investigator deems likely to affect nutrient absorption or the assessment of intestinal parameters;
- Use of antibiotics or probiotics within the past 4 weeks;
- Use of any protein powder, BCAA, creatine, HMB, etc., within the past 4 weeks;
- Use of medications that affect protein metabolism (e.g., glucocorticoids, androgenic drugs) within the past 4 weeks;
- Presence of severe cardiovascular, hepatic, renal, or metabolic disorders (e.g., uncontrolled hypertension, diabetes mellitus), or conditions that contraindicate participation in the physical performance test;
- History of severe musculoskeletal injury or recent surgery within the past 3 months;
- Pregnancy or lactation status;
- Other conditions under which the investigator deems participation in this study unsuitable, or where adherence to study protocols is unlikely.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site, 1 recruiting
- Recruiting
Henan University of Technology
Zhengzhou, Henan
Fei Xu, + 86 13671979116, xu.fei@haut.edu.cn
About this study
Official title: A Randomized, Double-blind, Placebo-controlled Clinical Study Evaluating the Effects of Postbiotics on Protein Utilization, Body Composition, and Gut Microbiota in Adults
The goal of this clinical trial is to find out whether a daily postbiotic supplement can help healthy, physically active adults digest and absorb dietary protein better. The main question we aim to answer is: does taking a postbiotic for 12 weeks increase the levels of essential amino acids in the blood after eating a protein-rich meal? Participants will be randomly assigned to one of two groups. One group will receive the postbiotic supplement, and the other group will receive a placebo (a substance with no active therapeutic effect). Everyone will take their assigned supplement once daily for 12 weeks. During the study, participants will have regular health checks, including body composition and muscle strength tests, provide stool samples, and complete a protein tolerance test with blood samples taken before and after the meal. This study is important because it explores whether a postbiotic can help active adults get more benefit from the protein they eat, potentially offering a new way to support muscle and digestive health.
- Conditions
- Protein Utilization
- Being tested
- Inactivated Probiotics, Placebo
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Inactivated ProbioticsDietary supplement
Evaluate changes in postprandial plasma essential amino acid response, body composition, muscle-related markers, gut barrier function, and gut microbiota before and after the intervention.
PlaceboDietary supplement
Placebo
| Study group | Role | What they receive |
|---|---|---|
| Placebo Group | Placebo comparator | Not described Receives: Dietary Supplement: Placebo |
| Postbiotic group | Experimental | Not described Receives: Dietary Supplement: Inactivated Probiotics |
What is being measured
The primary outcome is the main question the study is designed to answer.
Postprandial plasma essential amino acid (EAA) response
A standardized protein load test
Measured: 12 weeks (fasting at 0 min, postprandial at 60 min, and postprandial at 120 min)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted28 Oct 2026
- Study start14 Oct 2026 (estimated)
- Primary completion6 Jan 2027 (estimated)
- Study completion6 Mar 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Protein UtilizationStudies of the same condition, open and under way.
- More trials run by Wecare Probiotics Co., Ltd.The sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 100 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Wecare Probiotics Co., Ltd.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07900204
- Sponsor's protocol ID
- WK20261021
- Status last verified
- Oct 2026
- First submitted
- 21 Oct 2026
- Last updated
- 28 Oct 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 28 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Randomized, Double-blind, Placebo-controlled Clinical Study Evaluating the Effects of Postbiotics on Protein Utilization, Body Composition, and Gut Microbiota in Adults
- ClinicalTrials.gov ID
- NCT07900204
- Acronym / sponsor ID
- WK20261021
- Conditions
- Protein Utilization
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 100 participants (estimated)
- Lead sponsor
- Wecare Probiotics Co., Ltd.Industry (pharma, biotech, devices)
- Study start
- 14 Oct 2026 (estimated)
- Primary completion
- 6 Jan 2027 (estimated)
- Study completion
- 6 Mar 2027 (estimated)
- First posted
- 28 Oct 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this clinical trial is to find out whether a daily postbiotic supplement can help healthy, physically active adults digest and absorb dietary protein better. The main question we aim to answer is: does taking a postbiotic for 12 weeks increase the levels of essential amino acids in the blood after eating a protein-rich meal? Participants will be randomly assigned to one of two groups. One group will receive the postbiotic supplement, and the other group will receive a placebo (a substance with no active therapeutic effect). Everyone will take their assigned supplement once daily for 12 weeks. During the study, participants will have regular health checks, including body composition and muscle strength tests, provide stool samples, and complete a protein tolerance test with blood samples taken before and after the meal. This study is important because it explores whether a postbiotic can help active adults get more benefit from the protein they eat, potentially offering a new way to support muscle and digestive health.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Placebo Group | Placebo comparator | Dietary Supplement: Placebo |
| Postbiotic group | Experimental | Dietary Supplement: Inactivated Probiotics |
Who may qualify
- Ages
- 18 to 45 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (5 listed)
- Age: 18-45 years; open to all genders;
- Body weight has remained stable over the preceding 3 months (change < 5%);
- Willing to maintain their previous dietary and exercise habits with minimal change during the study period;
- Have maintained regular training over the past 3 months, with an average of ≥ 3 sessions/week and each session lasting ≥ 30 minutes;
- Voluntarily participate and sign a written informed consent form, and be able to complete follow-up visits, blood sampling, stool sampling, and questionnaire completion as required.
Key exclusion criteria (8 listed)
- History of or current presence of severe gastrointestinal disorders (e.g., inflammatory bowel disease, significant malabsorption following gastrointestinal surgery), or other conditions that the investigator deems likely to affect nutrient absorption or the assessment of intestinal parameters;
- Use of antibiotics or probiotics within the past 4 weeks;
- Use of any protein powder, BCAA, creatine, HMB, etc., within the past 4 weeks;
- Use of medications that affect protein metabolism (e.g., glucocorticoids, androgenic drugs) within the past 4 weeks;
- Presence of severe cardiovascular, hepatic, renal, or metabolic disorders (e.g., uncontrolled hypertension, diabetes mellitus), or conditions that contraindicate participation in the physical performance test;
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Inactivated ProbioticsEvaluate changes in postprandial plasma essential amino acid response, body composition, muscle-related markers, gut barrier function, and gut microbiota before and after the intervention. | Dietary supplement | Postbiotic group |
| PlaceboPlacebo | Dietary supplement | Placebo Group |
Primary outcome
Postprandial plasma essential amino acid (EAA) response
Time frame: 12 weeks (fasting at 0 min, postprandial at 60 min, and postprandial at 120 min)
A standardized protein load test
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 28 Oct 2026.
Related trials for Protein Utilization
RecruitingPhase 2
A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma
Multiple Myeloma
RecruitingPhase 2
Use of Isatuximab, Dexamethasone and Lenalidomide in a Go-Slow Fashion for Ultra-Frail Patients With Multiple Myeloma
Multiple Myeloma, Plasma Cell Leukemia
Not yet recruitingObservational study
Why Patients Decline or Are Being Deemed Ineligible to Receive Home-based Treatment: a Mixed Methods Study
Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma, Multiple Myeloma Progression
Not yet recruiting
The PIONEER Comparative Effectiveness Study - Project 2
Head Injury Trauma, Traumatic Brain Injury, Mild
Active, not recruitingObservational study
Non Interventional Study to Investigate the Safety and Effectiveness in Patients With Relapsed and Refractory Multiple Myeloma Treated With Elranatamab Under the Actual Use.
Relapsed and Refractory Multiple Myeloma (RRMM)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Inactivated Probiotics in people with Protein Utilization, run by Wecare Probiotics Co., Ltd. at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 28 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Fei Xu (+ 86 13671979116, xu.fei@haut.edu.cn), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Postprandial plasma essential amino acid (EAA) response (time frame: 12 weeks (fasting at 0 min, postprandial at 60 min, and postprandial at 120 min)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Oct 2026.